AMPH
Amphastar Pharmaceuticals Inc

1,128
Mkt Cap
$1.12B
Volume
740,834.00
52W High
$31.26
52W Low
$19.83
PE Ratio
10.33
AMPH Fundamentals
Price
$19.83
Prev Close
$21.01
Open
$20.35
50D MA
$27.09
Beta
0.77
Avg. Volume
475,604.32
EPS (Annual)
$2.03
P/B
1.22
Rev/Employee
$364,315.28
$1,661.95
Loading...
Loading...
News
all
press releases
Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 12-Month Low After Analyst Downgrade
Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year Low on Analyst Downgrade...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·4d ago
News Placeholder
Wells Fargo & Company Has Lowered Expectations for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price
Wells Fargo & Company decreased their target price on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an "overweight" rating for the company in a research note on Friday...
MarketBeat·4d ago
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down on Analyst Downgrade...
MarketBeat·4d ago
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $30.00 at Needham & Company LLC
Needham & Company LLC dropped their price objective on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a "buy" rating for the company in a report on Friday...
MarketBeat·5d ago
News Placeholder
TD Asset Management Inc Sells 103,038 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
TD Asset Management Inc decreased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 5.1% in the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·5d ago
News Placeholder
Amphastar Pharmaceuticals Q4 Earnings Call Highlights
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives on the company's fourth-quarter earnings call highlighted new FDA approvals, continued growth for BAQSIMI, and expectations for mid-to-high...
MarketBeat·5d ago
News Placeholder
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·5d ago
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -24.49% and -5.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.
Zacks·8d ago
<
1
2
...
>

Latest AMPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.